In this presentation, l will focus on the chemical modification of functional proteins for for pharmaceutical and medicinal applications.[1] For bioconjugation, we use a combined approach of recently developed chemoselective reactions and enzymatic ligations, for instance the so-called P5- or Tub-tag®-labeling.[2,3] By generating stable antibody-drug conjugates (ADCs),[3] structurally defined multivalent scaffolds[4] or cell-permeable antibodies via conjugating cyclic cell-penetrating peptides,[5] we provide new modalities for most challenging pharmaceutical targets, including next generation cancer therapeutics or novel inhibitors against viral infections.
References
[1] D. Schumacher, C.P.R. Hackenberger, Curr. Opin. Chem. Biol. 2014, 22, 62-69.
[2] a) M.-A. Kasper et al., Angew. Chem. Int. Ed. 2019, 58, 11625-11630; b) M.-A. Kasper et al., Angew. Chem. Int. Ed. 2019, 58, 11631-11636; c) M.-A. Kasper et al., Chem Sci. 2019, 10, 6322-6329; d) C.E. Stieger et al. Angew. Chem. Int. Ed. 2021, 60, 15359-15364.
[3] a) D. Schumacher et al., Angew. Chem. Int. Ed. 2015, 54(46), 13787-13791, b) D. Schumacher et al., Chem. Sci. 2017, 8, 3471-3478.
[4] D. Lauster et al., Nature Nanotech. 2020, 15, 373-379.
[5] a) N. Nischan et al., Angew. Chem. Int. Ed. 2015, 54(6), 1950-1953; b) H. Herce et al., Nature Chem. 2017, 9, 762-771; c) A.F.L. Schneider et al., Nature Chem. 2021, 13, 530-539.